Brivaracetam: a newly approved medication for epilepsy

IF 0.6 Q4 CLINICAL NEUROLOGY

Future Neurology Pub Date : 2019-08-01 DOI:10.2217/FNL-2015-0002

J. Oster

引用次数: 0

Abstract

Brivaracetam (BRV) in both the USA and EU was developed as a novel molecule for the adjunctive treatment of partial-onset (focal) seizures in patients ≥16 years of age and as of September 2017 was approved for use as monotherapy in the USA uniquely as an antiseizure medication that may be prescribed without a dose finding uptitration. This article reviews BRV's pharmacology, efficacy, safety and adverse event profiles, along with the relevant and noted regulatory hurdles in the USA and the EU. Available postmarketing data will also be summarized. Approximately 3000 patients were studied over about 9 years in the clinical trial program illustrating that BRV has efficacy at 50–200 mg/day with an acceptable adverse event profile.

查看原文本刊更多论文

Brivaracetam：一种新批准的治疗癫痫的药物

Brivaracetam（BRV）在美国和欧盟都被开发为一种新型分子，用于辅助治疗≥16岁患者的部分发作（局灶性）癫痫，截至2017年9月，它在美国被批准作为单一疗法使用，是一种独特的抗癫痫药物，可以在没有剂量发现增加的情况下开具处方。本文综述了BRV的药理学、疗效、安全性和不良事件概况，以及美国和欧盟的相关和注意到的监管障碍。还将汇总可用的上市后数据。在大约9年的临床试验项目中，对大约3000名患者进行了研究，表明BRV在50–200 mg/天时具有疗效，不良事件可接受。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Neurology CLINICAL NEUROLOGY-

CiteScore

2.10

自引率

0.00%

发文量

期刊介绍： The neurological landscape is changing rapidly. From the technological perspective, advanced molecular approaches and imaging modalities have greatly increased our understanding of neurological disease, with enhanced prospects for effective treatments in common but very serious disorders such as stroke, epilepsy, multiple sclerosis and Parkinson’s disease. Nevertheless, at the same time, the healthcare community is increasingly challenged by the rise in neurodegenerative diseases consequent upon demographic changes in developed countries.